The Valley Desk

NCT05945823 · Interventional trial

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Overall registry status Active not recruiting

Phase 2

Conditions Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Pancreatic Cancer, Siewert Type 1 GEJ Cancer

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov